Financial overview

Biosergen financial report data and keyfigures. History for income statement, balance sheet and cash flow.

Pre
Pre
Pre

Description

Biosergen conducts biopharmaceutical research and development through its subsidiary Biosergen AS. Biosergen is a so-called No Research Development Only company, which organizationally and financially focuses all its resources on clinical development. The company is developing BSG005, a potentially degrading antifungal, which has shown significant safety and potency advantages over competing antifungals. The biosergen will initially use BSG005 against invasive fungal infections such as immunosuppressed AIDS cancer and transplant patients.

Biotechnology